David Sallman

64PUBLICATIONS

420CO-AUTHORS

Regenerative medicine (incl. stem cells)Medical mycologyGene and molecular therapyHaematologyHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (64)

Sort by Publication Date:

|Jul 13, 2026

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jul 01, 2026

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

|Jun 29, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Jun 05, 2026

Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.

|May 06, 2026

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

|Apr 06, 2026

Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

Pageof 11

Frequent Collaborators

43 joint publications

Rami S Komrokji

20 joint publications

Eric Padron

14 joint publications

Jeffrey Lancet

14 joint publications

Onyee Chan

14 joint publications

Guillermo Garcia-Manero

10 joint publications

Mrinal Patnaik

10 joint publications

Naval G Daver

10 joint publications

Zhuoer Xie

8 joint publications

Andrew T Kuykendall

7 joint publications

Uwe Platzbecker

Frequent Collaborators

43 joint publications

Rami S Komrokji

20 joint publications

Eric Padron

14 joint publications

Jeffrey Lancet

14 joint publications

Onyee Chan